In wave 3 of the immuno-oncology surge things have slowed down, partly due to a raft of combination trials yet to read out and partly because the reality has finally hit that tumour heterogeneity means there will be variable patient responses.
This complexity can come about in many forms… immunosuppression, alterations in gene functions, resistance and immune escape, to name a few.
If we want to help more people respond to these therapies then before we can rush headlong into another round of combination trials, we first have to go back to looking carefully at the underlying biology of the diseases and listen to what the patient’s tumours are telling us in order to fix things.
To accomplish this feat requires considerable time, energy, effort, and a lot of bioinformatics.
In this post we explore five key talks that highlight different aspects of biomarkers of response and mechanisms of resistance. From there, we may see additional validation and prospective testing to determine how best to segment people so that they have the greatest chance of responding to the therapy administered.
One thing that most people don’t have these days is time, which is how we can help you because here’s a handy short cut to finding out more about five complex and diverse areas on biomarkers or IO resistance quickly and easily…